Head to Head Contrast: Alpha Cognition (OTC:ACOGF) & Eloxx Pharmaceuticals (NASDAQ:ELOX)

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Alpha Cognition (OTC:ACOGF) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Profitability

This table compares Eloxx Pharmaceuticals and Alpha Cognition’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Alpha Cognition	N/A	N/A	-522.43%

Institutional & Insider Ownership

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. 20.2% of Eloxx Pharmaceuticals shares are held by insiders. Comparatively, 31.5% of Alpha Cognition shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Eloxx Pharmaceuticals and Alpha Cognition”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	N/A	N/A	-$36.06 million	($9.07)	0.00
Alpha Cognition	N/A	N/A	-$13.77 million	C($0.12)	N/A

Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Alpha Cognition, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Eloxx Pharmaceuticals has a beta of -1702.41, suggesting that its share price is 170,341% less volatile than the S&P 500. Comparatively, Alpha Cognition has a beta of 2.8, suggesting that its share price is 180% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Eloxx Pharmaceuticals and Alpha Cognition, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	0	0	0	0	0.00
Alpha Cognition	0	0	2	0	3.00

Given Alpha Cognition’s stronger consensus rating and higher probable upside, analysts clearly believe Alpha Cognition is more favorable than Eloxx Pharmaceuticals.

Summary

Alpha Cognition beats Eloxx Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.

About Alpha Cognition

Alpha Cognition Inc., a clinical stage biopharmaceutical company, develops treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062 for the treatment of mild-to-moderate Alzheimer’s disease and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.